Precise. Personalized. Predictive.
Venebio Opioid Advisor Clinical Decision Support
Over the last two decades, prescription opioid-related overdose and deaths from opioid-induced respiratory depression (OIRD) have emerged as a major public health threat in the United States. Overdose deaths involving prescription opioids have quadrupled since 1999 and parallel the striking increase of U.S. sales and consumption of prescription opioids. From 1999 to 2015, more than 183,000 people have died in the U.S. from overdoses related to prescription opioids.
More about the opioid overdose epidemic.
In response to the public health threat posed by the opioid overdose epidemic, Venebio Group developed the Venebio Opioid Advisor (VOA) clinical decision support tool to support safer opioid prescribing.
The tool provides an evidence-based, quantitative estimate of a patient’s likelihood of experiencing a life-threatening opioid emergency in the next six months. It characterizes the patient’s specific risk factor profile and provides individualized, evidence-based, risk-mitigation interventions for the health care professional and patient.
More about Venebio Opioid Advisor.
The development of VOA built on our previously published predictive models and scoring systems that estimate the level of risk of experiencing an adverse outcome.
VOA has undergone extensive retrospective validation, initially in a case-control study of U.S. military veterans, followed by validation in a more representative population using the IMS PharMetrics Plus™ database of 18+ million prescription opioid users.
Implementing VOA can prevent more than 500 overdoses per 100,000 opioid recipients per year. This translates into preventing over 400 prescription opioid overdose-related emergency department visits, avoiding over 120 hospitalizations, and reducing annual health care costs by $2 million per 100,000 patients receiving opioid therapy.
More about our research.
Venebio Group will present at the upcoming Health 2.0 Annual Fall Conference in Santa Clara, CA on October 2, 2017. During the presentation, Mr. Mark Tripodi, Venebio’s Chief Development Officer, will highlight the Venebio Opioid Advisor clinical decision support tool and its benefits toward safer opioid prescribing.
Many healthcare provider and payer organizations are looking to leverage advanced health IT tools, such as data analytics and predictive modeling, to identify risk factors that can put patients at high risk for a prescription opioid overdose or addiction in order to intervene before an adverse event occurs. Read the […]
Venebio Group, a leader in personalized risk prediction algorithms, today announced that its risk-screening tool for opioid overdose, Venebio Opioid Advisor™ (VOA™), is now commercially available nationwide following the conclusion of its pilot phase. While much of the national attention around the opioid epidemic has focused on addiction, many unintentional […]
A recent study published in Pain Medicine validates the strong performance of Venebio Group’s risk index tool — Venebio Opioid Advisor (VOA) — at predicting the likelihood of a life-threatening overdose in patients taking a prescription opioid. Prescription opioid sales quadrupled in the United States between 1999 and 2010 , […]
Individuals suffering from a substance use disorder (SUD) or depression are among those at highest risk for a serious prescription opioid overdose, according to a study published in Pain Medicine. The retrospective, case-control study analyzed and compared patients with an opioid prescription from two health care claims databases: the U.S. […]
Eleven states are already allowing unilateral dispensing of Naloxone by a pharmacist. Most others allow dispensing without prescription or have standing order policies. Only five states have not allowed special access to naloxone. This link shows an updated map of naloxone access in community pharmacies across the United States, as of […]